MAP2K7 and non-small cell lung carcinoma: The European Medicines Agency and the United States Food and Drug Administration have approved dabrafenib, an anti-BRAF tyrosine kinase inhibitor (TKI), in combination with trametinib, an anti-MEK TKI, for the treatment of patients with <i>BRAF</i> V600E-mutated metastatic NSCLC.